메뉴 건너뛰기




Volumn 163, Issue 4, 2013, Pages 423-435

How I treat patients with relapsed chronic lymphocytic leukaemia

Author keywords

Chronic lymphocytic leukaemia; Leukaemia therapy; Refractory CLL; Relapsed CLL

Indexed keywords

ABT 199; ALEMTUZUMAB; BENDAMUSTINE; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN; LENALIDOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFATUMUMAB; PENTOSTATIN; PREDNISOLONE; PROTEIN INHIBITOR; RITUXIMAB; THROMBOPOIETIN; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 84886428456     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12549     Document Type: Review
Times cited : (5)

References (110)
  • 4
    • 27144548424 scopus 로고    scopus 로고
    • Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    • German CLL Study Group
    • Bergmann, M.A., Goebeler, M.E., Herold, M., Emmerich, B., Wilhelm, M., Ruelfs, C., Boening, L., Hallek, M.J. & German CLL Study Group (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica, 90, 1357-1364.
    • (2005) Haematologica , vol.90 , pp. 1357-1364
    • Bergmann, M.A.1    Goebeler, M.E.2    Herold, M.3    Emmerich, B.4    Wilhelm, M.5    Ruelfs, C.6    Boening, L.7    Hallek, M.J.8
  • 5
    • 84865861478 scopus 로고    scopus 로고
    • Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia
    • Billard, C. (2012) Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia. Leukemia, 26, 2032-2038.
    • (2012) Leukemia , vol.26 , pp. 2032-2038
    • Billard, C.1
  • 14
    • 56249095457 scopus 로고    scopus 로고
    • Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
    • Castro, J.E., Sandoval-Sus, J.D., Bole, J., Rassenti, L. & Kipps, T.J. (2008) Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia, 22, 2048-2053.
    • (2008) Leukemia , vol.22 , pp. 2048-2053
    • Castro, J.E.1    Sandoval-Sus, J.D.2    Bole, J.3    Rassenti, L.4    Kipps, T.J.5
  • 17
    • 77952965028 scopus 로고    scopus 로고
    • Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin
    • Chu, C.C., Catera, R., Zhang, L., Didier, S., Agagnina, B.M., Damle, R.N., Kaufman, M.S., Kolitz, J.E., Allen, S.L., Rai, K.R. & Chiorazzi, N. (2010) Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood, 115, 3907-3915.
    • (2010) Blood , vol.115 , pp. 3907-3915
    • Chu, C.C.1    Catera, R.2    Zhang, L.3    Didier, S.4    Agagnina, B.M.5    Damle, R.N.6    Kaufman, M.S.7    Kolitz, J.E.8    Allen, S.L.9    Rai, K.R.10    Chiorazzi, N.11
  • 18
    • 84871427640 scopus 로고    scopus 로고
    • Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG)
    • Cramer, P., Fink, A.M., Busch, R., Eichhorst, B., Wendtner, C.-M., Pflug, N., Schubert, F., Döhner, H., Rieger, M., Kneba, M., Mayer, J., Hallek, M. & Fischer, K. (2011) Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts), 118, 2863.
    • (2011) Blood (ASH Annual Meeting Abstracts) , vol.118 , pp. 2863
    • Cramer, P.1    Fink, A.M.2    Busch, R.3    Eichhorst, B.4    Wendtner, C.-M.5    Pflug, N.6    Schubert, F.7    Döhner, H.8    Rieger, M.9    Kneba, M.10    Mayer, J.11    Hallek, M.12    Fischer, K.13
  • 21
    • 41349122438 scopus 로고    scopus 로고
    • The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
    • UK National Cancer Research Institute NCRI, Haematological Oncology Clinical Studies Group & NCRI CLL Working Group
    • Dearden, C., Wade, R., Else, M., Richards, S., Milligan, D., Hamblin, T., Catovsky, D., UK National Cancer Research Institute NCRI, Haematological Oncology Clinical Studies Group & NCRI CLL Working Group (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood, 111, 1820-1826.
    • (2008) Blood , vol.111 , pp. 1820-1826
    • Dearden, C.1    Wade, R.2    Else, M.3    Richards, S.4    Milligan, D.5    Hamblin, T.6    Catovsky, D.7
  • 23
    • 70350475037 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
    • Delgado, J., Milligan, D.W. & Dreger, P. (2009) Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, 114, 2581-2588.
    • (2009) Blood , vol.114 , pp. 2581-2588
    • Delgado, J.1    Milligan, D.W.2    Dreger, P.3
  • 25
    • 0028987180 scopus 로고
    • p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
    • Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J. & Stilgenbauer, S. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
    • (1995) Blood , vol.85 , pp. 1580-1589
    • Dohner, H.1    Fischer, K.2    Bentz, M.3    Hansen, K.4    Benner, A.5    Cabot, G.6    Diehl, D.7    Schlenk, R.8    Coy, J.9    Stilgenbauer, S.10
  • 30
    • 40849094878 scopus 로고    scopus 로고
    • High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
    • Dungarwalla, M., Evans, S.O., Riley, U., Catovsky, D., Dearden, C.E. & Matutes, E. (2008) High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica, 93, 475-476.
    • (2008) Haematologica , vol.93 , pp. 475-476
    • Dungarwalla, M.1    Evans, S.O.2    Riley, U.3    Catovsky, D.4    Dearden, C.E.5    Matutes, E.6
  • 32
    • 80052716066 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • On behalf of the ESMO Guidelines Working Group
    • Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E. & Hallek, M. On behalf of the ESMO Guidelines Working Group (2011) Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22, vi50-vi54.
    • (2011) Annals of Oncology , vol.22
    • Eichhorst, B.1    Dreyling, M.2    Robak, T.3    Montserrat, E.4    Hallek, M.5
  • 33
    • 34249774066 scopus 로고    scopus 로고
    • Comprehensive geriatric assessment for older patients with cancer
    • Extermann, M. & Hurria, A. (2007) Comprehensive geriatric assessment for older patients with cancer. Journal of Clinical Oncology, 25, 1824-1831.
    • (2007) Journal of Clinical Oncology , vol.25 , pp. 1824-1831
    • Extermann, M.1    Hurria, A.2
  • 38
    • 77953811725 scopus 로고    scopus 로고
    • Cancer stem cells: back to Darwin?
    • Greaves, M. (2010) Cancer stem cells: back to Darwin? Seminars in Cancer Biology, 20, 65-70.
    • (2010) Seminars in Cancer Biology , vol.20 , pp. 65-70
    • Greaves, M.1
  • 40
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • International Workshop on Chronic Lymphocytic Leukemia
    • Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R., Kipps, T.J. & International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3    Caligaris-Cappio, F.4    Dighiero, G.5    Döhner, H.6    Hillmen, P.7    Keating, M.J.8    Montserrat, E.9    Rai, K.R.10    Kipps, T.J.11
  • 42
    • 33646477111 scopus 로고    scopus 로고
    • Autoimmune complications of chronic lymphocytic leukemia
    • Hamblin, T.J. (2006) Autoimmune complications of chronic lymphocytic leukemia. Seminars in Oncology, 33, 230-239.
    • (2006) Seminars in Oncology , vol.33 , pp. 230-239
    • Hamblin, T.J.1
  • 45
    • 68449102378 scopus 로고    scopus 로고
    • A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia
    • Kaufman, M., Limaye, S.A., Driscoll, N., Johnson, C., Caramanica, A., Lebowicz, Y., Patel, D., Kohn, N. & Rai, K. (2009) A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leukemia & Lymphoma, 50, 892-899.
    • (2009) Leukemia & Lymphoma , vol.50 , pp. 892-899
    • Kaufman, M.1    Limaye, S.A.2    Driscoll, N.3    Johnson, C.4    Caramanica, A.5    Lebowicz, Y.6    Patel, D.7    Kohn, N.8    Rai, K.9
  • 50
    • 84878898569 scopus 로고    scopus 로고
    • Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen
    • Kneba, M., Fischer, K., Bahlo, J., Fink, A.M., Busch, R., Bottcher, S., Dohner, H., Mayer, J., Dreger, P., Maurer, C., Engelke, A., Eichhorst, B.F., Wendtner, C.-M., Stilgenbauer, S. & Hallek, M. (2012) Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. Blood (ASH Annual Meeting Abstracts), 120, 435.
    • (2012) Blood (ASH Annual Meeting Abstracts) , vol.120 , pp. 435
    • Kneba, M.1    Fischer, K.2    Bahlo, J.3    Fink, A.M.4    Busch, R.5    Bottcher, S.6    Dohner, H.7    Mayer, J.8    Dreger, P.9    Maurer, C.10    Engelke, A.11    Eichhorst, B.F.12    Wendtner, C.-M.13    Stilgenbauer, S.14    Hallek, M.15
  • 54
    • 78650017999 scopus 로고    scopus 로고
    • Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
    • Lin, T.S., Donohue, K.A., Byrd, J.C., Lucas, M.S., Hoke, E.E., Bengtson, E.M., Rai, K.R., Atkins, J.N., Link, B.K. & Larson, R.A. (2010) Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. Journal of Clinical Oncology, 28, 4500-4506.
    • (2010) Journal of Clinical Oncology , vol.28 , pp. 4500-4506
    • Lin, T.S.1    Donohue, K.A.2    Byrd, J.C.3    Lucas, M.S.4    Hoke, E.E.5    Bengtson, E.M.6    Rai, K.R.7    Atkins, J.N.8    Link, B.K.9    Larson, R.A.10
  • 56
    • 0036683449 scopus 로고    scopus 로고
    • Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    • Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768-773.
    • (2002) Blood , vol.100 , pp. 768-773
    • Lundin, J.1    Kimby, E.2    Bjorkholm, M.3    Broliden, P.4    Celsing, F.5    Hjalmar, V.6    Mollgard, L.7    Rebello, P.8    Hale, G.9    Waldmann, H.10    Mellstedt, H.11    Osterborg, A.12
  • 61
    • 79959467722 scopus 로고    scopus 로고
    • Autografting CLL: the game is over!
    • Montserrat, E. & Gribben, J.G. (2011) Autografting CLL: the game is over! Blood, 117, 6057-6058.
    • (2011) Blood , vol.117 , pp. 6057-6058
    • Montserrat, E.1    Gribben, J.G.2
  • 63
    • 0037106257 scopus 로고    scopus 로고
    • Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
    • Morrison, V.A. (2002) Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. Journal of Clinical Oncology, 20, 3878-3884.
    • (2002) Journal of Clinical Oncology , vol.20 , pp. 3878-3884
    • Morrison, V.A.1
  • 66
    • 84886424411 scopus 로고    scopus 로고
    • A randomised dose de-escalation safety study of Oral Fludarabine, {+/-}Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years - end of recruitment analysis of response and toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
    • Mulligan, S.P., Gill, D.S., Turner, P., Renwick, W.E.P., Harrup, R., Latimer, M., Mackinlay, N., Berkahn, L., Simpson, D., Campbell, P., Tiley, C., Cull, G., Collins, M., Cortissos, P., Sulda, M., Best, G. & Kuss, B.J. (2012) A randomised dose de-escalation safety study of Oral Fludarabine, {+/-}Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years - end of recruitment analysis of response and toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood (ASH Annual Meeting Abstracts), 120, 436.
    • (2012) Blood (ASH Annual Meeting Abstracts) , vol.120 , pp. 436
    • Mulligan, S.P.1    Gill, D.S.2    Turner, P.3    Renwick, W.E.P.4    Harrup, R.5    Latimer, M.6    Mackinlay, N.7    Berkahn, L.8    Simpson, D.9    Campbell, P.10    Tiley, C.11    Cull, G.12    Collins, M.13    Cortissos, P.14    Sulda, M.15    Best, G.16    Kuss, B.J.17
  • 70
    • 33746137366 scopus 로고    scopus 로고
    • Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
    • Pettitt, A.R., Matutes, E. & Oscier, D. (2006) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20, 1441-1445.
    • (2006) Leukemia , vol.20 , pp. 1441-1445
    • Pettitt, A.R.1    Matutes, E.2    Oscier, D.3
  • 74
    • 68449089448 scopus 로고    scopus 로고
    • Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis
    • Raanani, P., Gafter-Gvili, A., Paul, M., Ben-Bassat, I., Leibovici, L. & Shpilberg, O. (2009) Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leukemia & Lymphoma, 50, 764-772.
    • (2009) Leukemia & Lymphoma , vol.50 , pp. 764-772
    • Raanani, P.1    Gafter-Gvili, A.2    Paul, M.3    Ben-Bassat, I.4    Leibovici, L.5    Shpilberg, O.6
  • 79
    • 0017730147 scopus 로고
    • Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia
    • Sawitsky, A., Rai, K.R., Glidewell, O. & Silver, R.T. (1977) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood, 50, 1049-1059.
    • (1977) Blood , vol.50 , pp. 1049-1059
    • Sawitsky, A.1    Rai, K.R.2    Glidewell, O.3    Silver, R.T.4
  • 82
    • 33750577939 scopus 로고    scopus 로고
    • Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
    • Shanafelt, T.D. (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 4634-4641.
    • (2006) Journal of Clinical Oncology , vol.24 , pp. 4634-4641
    • Shanafelt, T.D.1
  • 84
    • 84880276168 scopus 로고    scopus 로고
    • Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
    • Shanafelt, T.D., Ramsay, A.G., Zent, C.S., Leis, J.F., Tun, H.W., Call, T.G., Laplant, B., Bowen, D., Pettinger, A., Jelinek, D.F., Hanson, C.A. & Kay, N.E. (2013) Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood, 121, 4137-4141.
    • (2013) Blood , vol.121 , pp. 4137-4141
    • Shanafelt, T.D.1    Ramsay, A.G.2    Zent, C.S.3    Leis, J.F.4    Tun, H.W.5    Call, T.G.6    Laplant, B.7    Bowen, D.8    Pettinger, A.9    Jelinek, D.F.10    Hanson, C.A.11    Kay, N.E.12
  • 88
    • 80054853285 scopus 로고    scopus 로고
    • B-cell receptor signaling in chronic lymphocytic leukemia
    • Stevenson, F.K., Krysov, S., Davies, A.J., Steele, A.J. & Packham, G. (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood, 118, 4313-4320.
    • (2011) Blood , vol.118 , pp. 4313-4320
    • Stevenson, F.K.1    Krysov, S.2    Davies, A.J.3    Steele, A.J.4    Packham, G.5
  • 91
    • 0036122035 scopus 로고    scopus 로고
    • High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma
    • Summerfield, G.P., Taylor, P.R.A., Mounter, P.J. & Proctor, S.J. (2002) High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma. British Journal of Haematology, 116, 781-786.
    • (2002) British Journal of Haematology , vol.116 , pp. 781-786
    • Summerfield, G.P.1    Taylor, P.R.A.2    Mounter, P.J.3    Proctor, S.J.4
  • 96
    • 0037089334 scopus 로고    scopus 로고
    • The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes
    • Till, K., Lin, K., Zuzel, M. & Cawley, J. (2002) The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood, 99, 2977-2984.
    • (2002) Blood , vol.99 , pp. 2977-2984
    • Till, K.1    Lin, K.2    Zuzel, M.3    Cawley, J.4
  • 100
    • 0042236345 scopus 로고    scopus 로고
    • Mechanism of action and resistance to monoclonal antibody therapy
    • Villamor, N., Montserrat, E. & Colomer, D. (2003) Mechanism of action and resistance to monoclonal antibody therapy. Seminars in Oncology, 30, 424-433.
    • (2003) Seminars in Oncology , vol.30 , pp. 424-433
    • Villamor, N.1    Montserrat, E.2    Colomer, D.3
  • 101
    • 84878396846 scopus 로고    scopus 로고
    • SF3B1 mutations in chronic lymphocytic leukemia
    • Wan, Y. & Wu, C.J. (2013) SF3B1 mutations in chronic lymphocytic leukemia. Blood, 121, 4627-4634.
    • (2013) Blood , vol.121 , pp. 4627-4634
    • Wan, Y.1    Wu, C.J.2
  • 105
    • 84865176364 scopus 로고    scopus 로고
    • The B-cell receptor signaling pathway as a therapeutic target in CLL
    • Woyach, J.A., Johnson, A.J. & Byrd, J.C. (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood, 120, 1175-1184.
    • (2012) Blood , vol.120 , pp. 1175-1184
    • Woyach, J.A.1    Johnson, A.J.2    Byrd, J.C.3
  • 106
    • 33644545429 scopus 로고    scopus 로고
    • Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
    • Yeo, W. & Johnson, P.J. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology (Baltimore, MD), 43, 209-220.
    • (2006) Hepatology (Baltimore, MD) , vol.43 , pp. 209-220
    • Yeo, W.1    Johnson, P.J.2
  • 107
    • 70350511471 scopus 로고    scopus 로고
    • Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
    • Zenz, T., Häbe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Döhner, H. & Stilgenbauer, S. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.
    • (2009) Blood , vol.114 , pp. 2589-2597
    • Zenz, T.1    Häbe, S.2    Denzel, T.3    Mohr, J.4    Winkler, D.5    Buhler, A.6    Sarno, A.7    Groner, S.8    Mertens, D.9    Busch, R.10    Hallek, M.11    Döhner, H.12    Stilgenbauer, S.13
  • 109
  • 110
    • 84856553821 scopus 로고    scopus 로고
    • Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    • Zhou, Y., Tang, G., Medeiros, L.J., McDonnell, T.J., Keating, M.J., Wierda, W.G. & Wang, S.A. (2012) Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Modern Pathology, 25, 237-245.
    • (2012) Modern Pathology , vol.25 , pp. 237-245
    • Zhou, Y.1    Tang, G.2    Medeiros, L.J.3    McDonnell, T.J.4    Keating, M.J.5    Wierda, W.G.6    Wang, S.A.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.